Liquid-crystalline medium and liquid-crystal display comprising the same

US10774061B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10774061-B2
Application numberUS-201816021657-A
CountryUS
Kind codeB2
Filing dateJun 28, 2018
Priority dateJun 30, 2017
Publication dateSep 15, 2020
Grant dateSep 15, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention relates to a liquid-crystalline medium, preferably having a nematic phase and dielectric anisotropy of 0.5 or more, which comprises one or more compounds of formula S in which denotes and to the use thereof in an electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect, to displays of this type which contain a liquid-crystalline medium of this type, and to the use of the compounds of formula S for the improvement of the transmission and/or response times of a liquid-crystalline medium which comprises one or more additional mesogenic compounds.

First claim

Opening claim text (preview).

The invention claimed is: 1. A liquid-crystalline medium comprising one or more compounds of formula S in which  denotes  denotes, in each occurrence independently of each other, n denotes 1 or 2, R S denotes alkyl, alkoxy, fluorinated alkyl or fluorinated alkoxy, wherein one —CH 2 — group may be replaced by cyclopropylene, 1,3-cyclobutylene, 1,3-cyclopentylene, or 1,3-cyclo-pentenylene, or denotes alkenyl, alkenyloxy, alkoxyalkyl or fluorinated alkenyl having 2 to 7 C atoms, wherein one —CH 2 — group may be replaced by cyclopropylene, 1,3-cyclobutylene, 1,3-cyclopentylene, or 1,3-cyclo-pentenylene, and X S denotes F, Cl, CN, NCS, fluorinated alkyl, fluorinated alkenyl, fluorinated alkoxy or fluorinated alkenyloxy. 2. The medium according to claim 1 , wherein the one or more compounds of formula S are selected from the group consisting of compounds of formulae S-1 and S-2: in which R S denotes alkyl, alkoxy, fluorinated alkyl or fluorinated alkoxy, or alkenyl, alkenyloxy, alkoxyalkyl or fluorinated alkenyl having 2 to 7 C atoms, and X S denotes F, Cl, CN, NCS, fluorinated alkyl, fluorinated alkenyl, fluorinated alkoxy or fluorinated alkenyloxy. 3. The medium according to claim 2 , comprising one or more compounds of formula formulae S-1 and one or more compounds of formula S-2. 4. The medium according to claim 1 , further comprising one or more compounds of formulae II and/or III: in which R 2 denotes alkyl, alkoxy, fluorinated alkyl or fluorinated alkoxy having 1 to 7 C atoms, or alkenyl, alkenyloxy, alkoxyalkyl or fluorinated alkenyl having 2 to 7 C atoms, on each appearance, independently of one another, denote L 21 and L 22 denote H or F, X 2 denotes halogen, halogenated alkyl or alkoxy having 1 to 3 C atoms or halogenated alkenyl or alkenyloxy having 2 or 3 C atoms, m denotes 0, 1, 2 or 3, R 3 denotes alkyl, alkoxy, fluorinated alkyl or fluorinated alkoxy having 1 to 7 C atoms, or alkenyl, alkenyloxy, alkoxyalkyl or fluorinated alkenyl having 2 to 7 C atoms on each appearance, independently of one another, are L 31 and L 32 , independently of one another, denote H or F, X 3 denotes halogen, halogenated alkyl or alkoxy having 1 to 3 C atoms or halogenated alkenyl or alkenyloxy having 2 or 3 C atoms, F, Cl, —OCF 3 , —OCHF 2 , O—CH 2 CF 3 , —O—CH═CF 2 , —O—CH═CH 2 or —CF 3 , Z 3 denotes —CH 2 CH 2 —, —CF 2 CF 2 —, —COO—, trans-CH═CH—, trans-CF═CF—, —CH 2 O— or a single bond, and n denotes 0, 1, 2 or 3. 5. The medium according to claim 1 , further comprising one or more compounds of formulae IV and/or V: in which R 41 and R 42 each, independently of one another, denotes alkyl, alkoxy, fluorinated alkyl or fluorinated alkoxy having 1 to 7 C atoms, or alkenyl, alkenyloxy, alkoxyalkyl or fluorinated alkenyl having 2 to 7 C atoms, independently of one another and, if  occurs twice, also these independently of one another, denote Z 41 and Z 42 , independently of one another and, if Z 41 occurs twice, also these independently of one another, denote —CH 2 CH 2 —, —COO—, trans-CH═CH—, trans-CF═CF—, —CH 2 O—, —CF 2 O—, —C≡C— or a single bond, p denotes 0, 1 or 2, R 51 and R 52 each, independently of one another, denotes alkyl, alkoxy, fluorinated alkyl or fluorinated alkoxy having 1 to 7 C atoms, or alkenyl, alkenyloxy, alkoxyalkyl or fluorinated alkenyl having 2 to 7 C atoms, if present, each, independently of one another, denote Z 51 to Z 53 each, independently of one another, denote —CH 2 —CH 2 —, —CH 2 —O—, —CH═CH—, —C≡C—, —COO— or a single bond, and i and j each, independently of one another, denotes 0 or 1. 6. The medium according to claim 5 , further comprising one or more compounds of formulae VI to IX: wherein R 61 denotes an unsubstituted alkyl radical having 1 to 7 C atoms, an unsubstituted alkenyl radical having 2 to 7 C atoms, an unsubstituted alkoxy radical having 1 to 6 C atoms or an unsubstituted alkenyloxy radical having 2 to 6 C atoms, R 62 denotes an unsubstituted alkyl radical having 1 to 7 C atoms, an unsubstituted alkoxy radical having 1 to 6 C atoms or an unsubstituted alkenyloxy radical having 2 to 6 C atoms, and I denotes 0 or 1, R 71 denotes an unsubstituted alkyl radical having 1 to 7 C atoms, or an unsubstituted alkenyl radical having 2 to 7 C atoms, R 72 denotes an unsubstituted alkyl radical having 1 to 7 C atoms, an unsubstituted alkoxy radical having 1 to 6 C atoms or an unsubstituted alkenyloxy radical having 2 to 6 C atoms,  denotes R 81 denotes an unsubstituted alkyl radical having 1 to 7 C atoms, or an unsubstituted alkenyl radical having 2 to 7 C atoms, R 82 denotes an unsubstituted alkyl radical having 1 to 7 C atoms, an unsubstituted alkoxy radical having 1 to 6 C atoms or an unsubstituted alkenyloxy radical having 2 to 6 C atoms,  denotes Z 8 denotes —(C═O)—O—, —CH 2 —O—, —CF 2 —O— or —CH 2 —CH 2 —, o denotes 0 or 1, R 91 and R 92 each, independently of one another denotes an unsubstituted alkyl radical having 1 to 7 C atoms, an unsubstituted alkoxy radical having 1 to 6 C atoms or an unsubstituted alkenyl

Assignees

Inventors

Classifications

  • having oxygen as hetero atom (sugars C09K19/0422) · CPC title

  • in which the rings are linked by a chain containing carbon and oxygen atoms, e.g. esters or ethers · CPC title

  • having sulfur as hetero atom · CPC title

  • characterised by components which are not liquid crystals, e.g. additives {with special physical aspect: solvents, solid particles} · CPC title

  • based on liquid crystals, e.g. single liquid crystal display cells · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10774061B2 cover?
The invention relates to a liquid-crystalline medium, preferably having a nematic phase and dielectric anisotropy of 0.5 or more, which comprises one or more compounds of formula S in which denotes …
Who is the assignee on this patent?
Merck Patent Gmbh
What technology area does this patent fall under?
Primary CPC classification C09K19/3491. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).